Skip to main content

Peer Review reports

From: Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Original Submission
26 Sep 2020 Submitted Original manuscript
28 Oct 2020 Reviewed Reviewer Report
13 Dec 2020 Reviewed Reviewer Report
26 Feb 2021 Author responded Author comments - Luis D Borrero-Garcia
Resubmission - Version 2
26 Feb 2021 Submitted Manuscript version 2
27 Mar 2021 Reviewed Reviewer Report
28 Mar 2021 Reviewed Reviewer Report
4 May 2021 Reviewed Reviewer Report
12 May 2021 Author responded Author comments - Luis D Borrero-Garcia
Resubmission - Version 3
12 May 2021 Submitted Manuscript version 3
Publishing
17 May 2021 Editorially accepted
1 Jun 2021 Article published 10.1186/s12885-021-08366-7

You can find further information about peer review here.

Back to article page